Lactiplantibacillus Plantarum PD01 Supplementation Reduces Microplastics and Microplastic-associated Chemicals in Humans

Lactiplantibacillus Plantarum PD01 Supplementation Reduces Microplastics and Microplastic-associated Chemicals in Humans: A Randomized, Double-blind, Placebo-controlled Trial

The study attempts to conduct randomized double-blind controlled trials to understand whether daily exposure to microplastics (MPs) can cause potential impacts on human health, explore whether the intake of Lactiplantibacillus plantarum PD01 can alleviate potential obesity-related damages caused by MPs, and provide a scientific basis for the prevention and nutritional intervention of health hazards caused by MP exposure.

Inclusion Criteria:

• Age 18-65 years.
• Body Mass Index (BMI) ≥ 24.0 kg/m² or meeting the criteria for central obesity (waist circumference ≥ 90 cm for men, ≥ 85 cm for women); participants with mild abnormalities in blood lipids and liver function indicators will be prioritized.
• Permanent residents of the local area during the trial period, with no plans for long-term business trips or travel.
• Fully understand the research content and voluntarily sign the informed consent form.

Exclusion Criteria:

• Diagnosed congenital or acquired immunodeficiency diseases, severe allergic diseases, active gastrointestinal diseases, and other acute or chronic diseases requiring long-term treatment.
• Use of antibiotics, immunosuppressants, probiotics, prebiotics, synbiotics, or other drugs that clearly affect gut microbiota or gastrointestinal function within the 6 months prior to the trial.
• Regular intake of nutritional supplements (such as vitamins, fish oil, etc.) within the 6 months prior to the trial.
• Having bad lifestyle habits such as smoking or alcoholism.
• Women who are pregnant, lactating, or planning to become pregnant.
• Weight change exceeding 5% of body weight within the 3 months prior to the trial.
• Participation in or planning to participate in any other clinical intervention studies.